^
Association details:
| Biomarker: | TET2 mutation |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Regimen: | CHOP (cyclophosphamide + doxorubicin hydrochloride + + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study
Published date:
04/11/2021
Excerpt:
This phase 2 study prioritized enrollment of PTCL-TFH. Subjects received CHOP on day 1 of each cycle for 6 cycles. Oral azacitidine (aza)...For all patients, TET2 mutations were significantly associated with CR (p=0.007), favorable PFS (p=0.004) and OS (p=0.015), while DNMT3A mutations were associated with adverse PFS (p=0.016). Within the PTCL-TFH subgroup, TET2 mutations were associated with favorable PFS (p=0.014).
Secondary therapy:
azacitidine
DOI:
10.1182/blood-2021-145495
Trial ID:
